Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 5/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4734075 | 0.89 | BRD4 (0.57) | LMNATSHRBRD4NOTUMRIPK1 | |
| SCHEMBL16862950 | 0.86 | BRD4 (0.59) | BRD4NOTUMRIPK1KLKB1 | |
| SCHEMBL17241086 | 0.84 | P2RX7 (0.46) | SMN1; SMN2LMNABRD4NOTUMRIPK1 | |
| SCHEMBL17166094 | 0.83 | TSHR (0.46) | SMN1; SMN2LMNATSHRBRD4NOTUM | |
| SCHEMBL16862955 | 0.82 | ALDH1A1 (0.60) | LMNATSHRALDH1A1GAAKDM4E | |
| Trifluoroacetic Acid SCHEMBL4737901 | 0.81 | BRD4 (0.51) | TSHRBRD4NOTUMRIPK1L3MBTL1 | |
| SCHEMBL4737896 | 0.78 | BRD4 (0.41) | LMNABRD4NOTUMRIPK1ALDH1A1 | |
| SCHEMBL2360506 | 0.78 | BRD4 (0.47) | SMN1; SMN2BRD4ALDH1A1TP53 | |
| SCHEMBL13363565 | 0.77 | BRD4 (0.46) | SMN1; SMN2LMNABRD4NOTUMRIPK1 | |
| SCHEMBL15701785 | 0.76 | BRD4 (0.47) | SMN1; SMN2LMNATSHRBRD4NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1485375-B1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2009-06-17 | — | — | EP | disclosed |
| US-7485638-B2 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2009-02-03 | — | — | US | disclosed |
| US-20050256311-A1 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| EP-0116205-A1 | 4(5)-Acetyl-2-methylimidazole process | PFIZER INC. (US) | 1984-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256311-A1 | Pyrimidine compounds | TYMP, TYMS, CCNT1 | SMN1; SMN2 2086/4885LMNA 2057/4885TSHR 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.